BRCA1 and breast cancer: The results from studies of PARPi in advanced and metastatic BC suggest that these agents are active against BC in women with germline BRCA1/2 loss-of-function mutations, but response rates remain around 60%.61 Lack of response in BRCA1/2m carriers may be due to several mechanisms of resistance69,70 (Fig. 1).